SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges on receiving USFDA approval for generic Lidex Ointment

02 Aug 2017 Evaluate

Lupin is currently trading at Rs. 1032.30, up by 14.30 points or 1.40% from its previous closing of Rs. 1018.00 on the BSE.

The scrip opened at Rs. 1030.00 and has touched a high and low of Rs. 1036.00 and Rs. 1022.00 respectively. So far 56684 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1747.80 on 02-Aug-2016 and a 52 week low of Rs. 1015.60 on 01-Aug-2017.

Last one week high and low of the scrip stood at Rs. 1132.00 and Rs. 1015.60 respectively. The current market cap of the company is Rs. 46728.80 crore.

The promoters holding in the company stood at 46.70%, while institutions and non-institutions held 40.66% and 12.63% respectively.

Lupin has received final approval for its Fluocinonide Topical Ointment USP, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of County Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%. Lidex Ointment had US sales of $40.3 million, as per IMS MAT March 2017.

Lupin’s Fluocinonide Topical Ointment USP, 0.05% is AB rated generic equivalent of County Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2263.00 -114.90 (-4.83%)
11-May-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1882.20
Dr. Reddys Lab 1290.00
Cipla 1341.45
Zydus Lifesciences 944.85
Lupin 2263.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×